Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03114462 · ClinicalTrials.gov registry record · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
A Phase 1 study of Malignant Neoplasms of Respiratory and Intrathoracic Organs and Squamous Cell Carcinoma of the Larynx, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT03114462: Recruiting Phase 1 study of Malignant Neoplasms of Respiratory and Intrathoracic Organs and Squamous Cell Carcinoma of the Larynx, sponsored by M.D. Anderson Cancer Center.
NCT03114462 is a Phase 1 study of Malignant Neoplasms of Respiratory and Intrathoracic Organs and Squamous Cell Carcinoma of the Larynx that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03114462, a Phase 1 study of Malignant Neoplasms of Respiratory and Intrathoracic Organs and Squamous Cell Carcinoma of the Larynx, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.
Primary Outcome
Toxicity graded using the NCI Common Toxicity Criteria for Adverse Events (CTCAE) v. 4.0.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaires
- RADIATION Stereotactic Hypofractionated Radioablation
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-08-09 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 1 |
What NCT03114462 shows while recruiting
NCT03114462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Malignant Neoplasms of Respiratory and Intrathoracic Organs appearing as the primary indexed condition, and to 2 interventions - of which Questionnaires is the first listed.
NCT03114462 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03114462 about?
NCT03114462 is a clinical study titled "Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer". To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.
What is the current status of trial NCT03114462?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-08-09. Estimated completion is 2027-06-01.
What conditions does trial NCT03114462 study?
This clinical trial studies the following conditions: Malignant Neoplasms of Respiratory and Intrathoracic Organs, Squamous Cell Carcinoma of the Larynx.
What interventions are being tested in trial NCT03114462?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Stereotactic Hypofractionated Radioablation (RADIATION).
Who is sponsoring clinical trial NCT03114462?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03114462 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasms of Respiratory and Intrathoracic Organs
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03114462's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
- NCT06673329 · 11 participants · Phase 1
Brodalumab in the Treatment of Immune-Related Adverse Events
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI